
Innate Pharma S.A. IPHA
$ 1.68
-1.47%
Annual report 2024
added 12-13-2025
Innate Pharma S.A. Interest Expense 2011-2025 | IPHA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Innate Pharma S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 566 K | 640 K | 288 K | 312 K | 341 K | 204 K | 102 K | 113 K | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 640 K | 102 K | 321 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.76 | -0.73 % | $ 790 M | ||
|
Aclaris Therapeutics
ACRS
|
2.95 M | $ 3.01 | -1.15 % | $ 233 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 209.37 | -1.62 % | $ 5 B | ||
|
Aptevo Therapeutics
APVO
|
472 K | $ 0.52 | -44.08 % | $ 144 K | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.29 | 6.3 % | $ 7.92 B | ||
|
BioVie
BIVI
|
4.3 M | $ 1.16 | -8.66 % | $ 1.71 M | ||
|
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
4.08 M | $ 27.0 | 0.7 % | $ 1.31 B | ||
|
BeiGene, Ltd.
BGNE
|
-12.6 M | - | 0.49 % | $ 251 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 0.22 | 24.23 % | $ 479 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Calithera Biosciences
CALA
|
2.65 M | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
286 M | $ 583.31 | -1.33 % | $ 44.2 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.47 | -2.37 % | $ 15.5 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
1.04 M | $ 12.37 | - | $ 814 M | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-7.26 M | $ 10.71 | -0.88 % | $ 693 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 26.13 | -2.63 % | $ 1.68 M | ||
|
Biogen
BIIB
|
250 M | $ 176.07 | -0.15 % | $ 25.6 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
10.6 M | - | - | $ 7.29 B |